Volume | 778,717 |
|
|||||
News | - | ||||||
Day High | 32.72 | Low High |
|||||
Day Low | 31.04 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Arvinas Inc | ARVN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
31.73 | 31.04 | 32.72 | 32.37 | 31.60 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
11,042 | 778,717 | $ 32.09 | $ 24,986,104 | - | 13.57 - 53.08 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:01:42 | 4 | $ 31.74 | USD |
Arvinas (ARVN) Options Flow Summary
Arvinas Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.21B | 68.08M | - | 78.5M | -367.3M | -5.39 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Arvinas News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARVN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 34.09 | 35.865 | 30.91 | 33.75 | 724,566 | -1.72 | -5.05% |
1 Month | 41.34 | 41.34 | 30.91 | 35.74 | 616,538 | -8.97 | -21.70% |
3 Months | 45.14 | 53.08 | 30.91 | 43.62 | 762,161 | -12.77 | -28.29% |
6 Months | 14.39 | 53.08 | 13.57 | 36.35 | 792,415 | 17.98 | 124.95% |
1 Year | 27.01 | 53.08 | 13.57 | 32.04 | 605,194 | 5.36 | 19.84% |
3 Years | 64.54 | 108.465 | 13.57 | 47.70 | 502,349 | -32.17 | -49.85% |
5 Years | 22.64 | 108.465 | 13.57 | 47.02 | 488,160 | 9.73 | 42.98% |
Arvinas Description
Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |